Jefferies analyst Kelly Shi initiated coverage of ProKidney with a Buy rating and $15 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PROK:
- ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
- ProKidney to Participate in Upcoming Investor Conferences
- ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease
